LogoCrystal's Coder Hub

D09.0

24 min read

🧬 ICD-10 CM D09.0 — Carcinoma in Situ of Bladder

Billable Code Confirmed

ICD-10 CM D09.0 is a valid, billable 5-character ICD-10-CM code effective for FY2026. It is classified under Chapter 2 (Neoplasms) in the D00-D09 in situ neoplasms block, within the D09 category for carcinoma in situ of other and unspecified sites. This code classifies pre-invasive (in situ) malignant neoplasms of the urinary bladder — specifically, carcinoma that has not yet penetrated the basement membrane of the urothelium. No additional characters are required; D09.0 is the terminal billable code at this level.

Non-Billable Parent Codes

  • D09 (Carcinoma in situ of other and unspecified sites) — Non-billable header category; lacks site specificity required for claim submission. The fifth character specifying site (bladder = D09.0, other urinary = D09.1x, eye = D09.2x, etc.) is always required.
  • D00-D09 block header — Non-billable; represents the in situ neoplasm range in the Tabular, not an assignable code.

Clinical Context

ICD-10 CM D09.0 represents bladder carcinoma in situ (CIS) — a flat, high-grade, non-invasive urothelial lesion confined to the mucosal layer that has not penetrated the basement membrane. Unlike the more common exophytic (papillary) superficial bladder tumors, bladder CIS is a flat lesion that is often invisible on cystoscopy without fluorescence-enhanced techniques, making it a particularly dangerous and clinically significant finding. Bladder CIS (Tis) carries a high risk of progression to invasive muscle-invasive bladder cancer if untreated, distinguishing it from lower-grade non-invasive papillary tumors. This high progression potential is why D09.0 represents a clinically urgent diagnosis despite its technically “non-invasive” ICD-10-CM classification — treatment escalation to BCG intravesical immunotherapy or even cystectomy is often required.

Code Classification

ICD-10 CM D09.0 is an in situ neoplasm (pre-invasive diagnosis) code — it classifies a malignant but non-invasive bladder lesion that has not breached the basement membrane. It is fundamentally different from invasive bladder cancer codes (C67.xx), is not a benign neoplasm code, and is not a history code. It is not an ICD-10-PCS code or a CPT code. The in situ classification means D09.0 does not drive HCC RAF contribution — a critical distinction from invasive bladder cancer for risk adjustment purposes.

🔍 Code Description

ICD-10 CM D09.0 classifies carcinoma in situ (CIS) of the urinary bladder — a high-grade, non-invasive urothelial carcinoma confined entirely to the urothelial lining (mucosa) without penetration of the basement membrane or invasion into the lamina propria, muscularis propria, or beyond. Histologically, bladder CIS consists of malignant urothelial cells that replace the normal epithelium but remain in a pre-invasive state; it is classified as Tis in the TNM staging system for bladder cancer. Unlike non-invasive papillary tumors (Ta, T1), which grow outward into the bladder lumen and are captured under different staging designations, CIS is a flat lesion that is particularly difficult to detect visually without photodynamic diagnosis or narrow-band imaging cystoscopy. The overwhelming histological subtype is urothelial (transitional cell) carcinoma in situ, though rare subtypes (squamous CIS, adenocarcinoma in situ) may also be captured under D09.0.

In the inpatient setting, D09.0 most commonly appears in the context of TURBT (transurethral resection of bladder tumor) admissions for diagnosis and treatment, BCG intravesical immunotherapy for high-risk non-muscle-invasive bladder cancer, or radical cystectomy admissions when CIS is refractory to intravesical therapy. Per ICD-10-CM Official Guideline I.C.2, in situ neoplasm codes represent a distinct and separate category from invasive malignancies — coders must never substitute D09.0 with an invasive code (C67.xx) unless the provider has explicitly documented invasion. Bladder CIS has one of the highest progression rates of any non-muscle-invasive bladder lesion, with up to 50-75% risk of progression to invasive disease without treatment, making accurate documentation and coding of D09.0 clinically and prognostically essential.

🌳 Code Tree / Hierarchy

D09  Carcinoma in situ of other and unspecified sites ❌ Non-billable
│
├── D09.0  Carcinoma in situ of bladder ◀ THIS CODE ✅ Billable
│
├── D09.1  Carcinoma in situ of other and unspecified urinary organs ❌ Non-billable
│   │
│   ├── D09.10  Carcinoma in situ of unspecified urinary organ ✅ Billable
│   └── D09.19  Carcinoma in situ of other urinary organs ✅ Billable
│
├── D09.2  Carcinoma in situ of eye ❌ Non-billable
│   │
│   ├── D09.20  Carcinoma in situ of unspecified eye ✅ Billable
│   ├── D09.21  Carcinoma in situ of right eye ✅ Billable
│   └── D09.22  Carcinoma in situ of left eye ✅ Billable
│
├── D09.3  Carcinoma in situ of thyroid and other endocrine glands ✅ Billable
│
├── D09.8  Carcinoma in situ of other specified sites ✅ Billable
│
└── D09.9  Carcinoma in situ, unspecified ✅ Billable

D09.0 vs. C67.xx — The In Situ vs. Invasive Line

The single most critical distinction for bladder neoplasm coding is whether the tumor is in situ (D09.0) or invasive (C67.xx). Invasive bladder cancer codes (e.g., C67.9 — malignant neoplasm of bladder, unspecified, or C67.1 — malignant neoplasm of dome of bladder) represent disease that has penetrated the basement membrane. The provider’s documentation — biopsy pathology confirming “carcinoma in situ” (no invasion) vs. “invasive urothelial carcinoma” — is the determinant. Do not upgrade to C67.xx without explicit provider documentation of invasion.

No ICD-10-CM Subsite Specificity for Bladder CIS

Unlike invasive bladder cancer (C67.0-C67.9), which has site-specific codes for the trigone, lateral wall, posterior wall, neck, dome, etc., D09.0 has no further subsite characters — bladder CIS is coded uniformly as D09.0 regardless of the specific location within the bladder. This reflects the clinical reality that CIS is often multifocal and diffuse throughout the urothelium. Cancer registry documentation should capture anatomical location(s) separately even though the ICD-10-CM code does not require subsite specificity.

âś… Includes

  • Bladder CIS (carcinoma in situ): The primary intended use; documentation stating “carcinoma in situ of the bladder,” “bladder CIS,” or “Tis, bladder” all map to D09.0.
  • Flat high-grade urothelial carcinoma in situ: The flat (non-papillary) variant of high-grade CIS; this histological description on pathology maps to D09.0 when no invasion is documented.
  • Non-invasive urothelial carcinoma in situ: When pathology confirms urothelial carcinoma in situ without basement membrane penetration, D09.0 is the correct code regardless of grade descriptor.
  • Tis designation in bladder TNM staging: The “Tis” (tumor in situ) designation from bladder TNM staging (AJCC 8th edition) corresponds directly to D09.0; this staging terminology in provider notes is sufficient documentation for D09.0 assignment.
  • Multifocal bladder CIS: When CIS is documented as multifocal (involving multiple bladder sites), D09.0 is still assigned once — there is no multiplicity modifier for in situ neoplasm codes in ICD-10-CM.

❌ Excludes

Excludes 1

These codes represent mutually exclusive conditions — do not assign with D09.0:

  • C67.x — Malignant neoplasm of bladder (invasive): These codes (C67.0-C67.9) represent invasive bladder carcinoma that has penetrated the basement membrane into the lamina propria, muscularis propria, or beyond. C67.xx and D09.0 represent different disease states for the same organ and cannot be coded together for the same bladder lesion. If a biopsy shows invasive carcinoma at one site and CIS at another distinct bladder site, query the provider about whether these represent separate primary tumors before assigning both codes. In most cases, when invasive carcinoma is confirmed, D09.0 is no longer applicable for that encounter.
  • Melanoma in situ (D03.x): Melanocytic in situ lesions of the bladder (extremely rare) are classified separately under D03 — D09.0 is specific to carcinoma (epithelial) in situ, not melanocytic in situ lesions.

CIS vs. Invasive Bladder Cancer — Critical Compliance Point

The most significant compliance risk with D09.0 is either (1) assigning D09.0 when the pathology actually documents invasive carcinoma (undercoding to in situ) or (2) assigning C67.xx when only CIS is documented (overcoding to invasive). Both errors misrepresent disease stage, affect DRG assignment, HCC capture, cancer registry staging, and treatment documentation. Biopsy pathology reports are the primary source, but the treating provider must clinically document and confirm the diagnosis as in situ or invasive — coders cannot independently determine this from pathology language alone. A CDI query is always appropriate when the provider’s note says “bladder cancer” without specifying in situ vs. invasive.

Excludes 2

These conditions are not included in D09.0 but may be coded additionally when clinically documented:

  • N30.x — Cystitis: Bladder CIS and concurrent cystitis (including BCG-induced cystitis, chemical cystitis, or infectious cystitis) may coexist and be coded together when both are documented. BCG-induced cystitis (a known complication of intravesical BCG therapy for bladder CIS) should be captured with the appropriate cystitis code when documented by the provider, as it may affect the clinical management and length of stay.
  • R31.x — Hematuria: Hematuria (gross or microscopic) is a common presenting symptom of bladder CIS and may be coded as an additional code when it is documented as a presenting sign. R31.0 (gross hematuria) may qualify as a CC in certain principal diagnosis scenarios, adding reimbursement value to the encounter.

đź“‹ Clinical Overview

Bladder CIS vs. Non-Invasive Papillary Tumors vs. Invasive Bladder Cancer

Understanding where D09.0 fits in the bladder cancer spectrum is essential for accurate code selection and CDI. CIS (Tis) is a flat, non-papillary, high-grade lesion with high progression risk — distinct from the lower-risk papillary Ta tumors and the already-invasive T1-T4 tumors. The treatment algorithm diverges sharply based on this classification, and documentation of the tumor type drives code selection entirely.

FeatureD09.0 — Bladder CIS (Tis)C67.xx — Invasive Bladder Cancer (T1-T4)Notes for Coders
TNM T stageTis — flat carcinoma in situT1 (lamina propria) through T4 (adjacent organs)Tis = D09.0; any T1 or higher = C67.xx
Growth patternFlat, diffuse, often multifocalPapillary (exophytic) or solid invasive massFlat vs. papillary appearance on cystoscopy
Basement membraneIntact — no invasionViolated — invasion presentPathology report defines this distinction
HCC mappingNot HCC-mapped (in situ)HCC 11 or HCC 12 depending on modelMajor RAF difference — critical for MA/ACO coding
Primary treatmentBCG intravesical immunotherapy; TURBT for diagnosisTURBT (T1), radical cystectomy (T2+)Treatment documentation confirms staging
Progression riskHigh — up to 50-75% risk of progression to invasive without treatmentAlready invasive — staging drives prognosisCDI: document if progression has occurred
ICD-10-CM codeD09.0C67.0-C67.9 (by bladder subsite)Subsite specificity required for C67.xx only
DRG (medical, no O.R.)DRG 698/699/700DRG 698/699/700 (similar medical DRG)O.R. procedure drives DRG differences

CDI Trigger — Progression to Invasive Disease

One of the highest-value CDI opportunities in bladder cancer inpatient encounters is identifying whether CIS has progressed to invasive carcinoma. If the current admission involves biopsy results showing lamina propria invasion (T1) or muscle invasion (T2), the correct code shifts from D09.0 to C67.9 or a more specific C67.xx code — a change that activates HCC capture and may affect DRG weight. If provider documentation says “bladder cancer” or “urothelial carcinoma” without specifying in situ vs. invasive, a CDI query for staging (Tis, Ta, T1, T2+) is warranted and clinically supported.

Manifestations & Symptom Burden

  • Gross or Microscopic Hematuria: The most common presenting symptom; when documented, R31.0 (gross hematuria) or R31.1 (benign essential microscopic hematuria) may be coded as additional diagnoses and can contribute to CC status in certain DRG scenarios.
  • Urinary Urgency/Frequency: Irritative voiding symptoms are common in bladder CIS, particularly with multifocal disease; when documented, R35.0 (frequency of micturition) or R39.15 (urgency of urination) may be coded as additional diagnoses.
  • BCG-Induced Cystitis (post-treatment): A common complication of intravesical BCG therapy; when documented, code the appropriate cystitis code (N30.80 or N30.90) alongside D09.0 and the adverse effect code if applicable.
  • Urinary Obstruction: Advanced or bulky in situ disease contributing to outflow obstruction; separately codeable (N13.x or R33.x) when documented.
  • Hydronephrosis: Bladder CIS involving the ureteral orifices may cause secondary hydronephrosis; when documented, N13.30 (hydronephrosis) is separately codeable and may affect CC/MCC status.

Manifestation Coding Reminder

ICD-10 CM D09.0 is a principal diagnosis code in most bladder CIS encounters — it does not follow another code as a manifestation. However, it may also appear as a secondary diagnosis when a patient admitted for another reason carries a known bladder CIS diagnosis. Per ICD-10-CM Guideline I.C.2.c, when the admission is for treatment of the neoplasm (TURBT, BCG, cystectomy), D09.0 is typically principal; when the admission is for a complication or an unrelated condition, D09.0 is additional. BCG instillation admissions follow guideline I.C.2.e — assign Z51.12 (encounter for antineoplastic immunotherapy) as principal with D09.0 as additional when BCG administration is the sole reason for admission.

đź’° HCC Risk Adjustment

HCC ModelHCC CategoryRAF WeightNotes
CMS-HCC V28 (PY2026)Not MappedN/AIn situ neoplasms excluded from HCC malignancy categories
CMS-HCC V24 (legacy, phased out 2026)Not MappedN/ASame exclusion — in situ ≠ active invasive malignancy
CDPS / MedicaidVaries by stateVariesSome state models may capture CIS as low-tier neoplasm

ICD-10 CM D09.0 does not map to any HCC category under CMS-HCC V28 (fully implemented PY2026) because HCC malignancy categories are reserved for active invasive malignancies. In situ neoplasm codes, including D09.0, are intentionally excluded from HCC capture on the basis that they represent pre-invasive lesions with significantly lower predicted costs than invasive cancers. This is a critical and commonly misunderstood distinction in risk adjustment coding: a patient with bladder CIS who has NOT progressed to invasive cancer should be coded D09.0 — and no HCC RAF weight is generated. If and when the provider documents progression to invasive bladder carcinoma (T1 or higher), the shift to a C67.xx code activates HCC capture and significantly increases the patient’s RAF score. CDI programs in Medicare Advantage should include bladder CIS as a surveillance flag: at every encounter, confirm with the provider whether the disease remains in situ or has progressed, to ensure timely transition to the appropriate invasive cancer code when clinically supported.

🏥 MS-DRG Assignment

ICD-10 CM D09.0 routes to MDC 11 — Diseases and Disorders of the Kidney and Urinary Tract when it is the principal diagnosis. DRG assignment then depends on whether a qualifying O.R. procedure is performed during the admission.

Clinical ScenarioPrincipal DxO.R. Procedure?MS-DRGNotes
Medical admission — BCG instillation onlyZ51.12 (with D09.0 as additional)NoDRG 698 (w/MCC), 699 (w/CC), 700 (w/o CC/MCC)Z51.12 is principal when BCG is the sole reason for admission; see sequencing note
Diagnostic cystoscopy with biopsyD09.0May qualify as O.R.DRG 673/674/675 or 698/699/700Cystoscopy with biopsy: confirm if it qualifies as O.R. in MS-DRG logic
TURBT performedD09.0Yes — TURBTDRG 673 (w/MCC), 674 (w/CC), 675 (w/o CC/MCC)TURBT is the primary O.R. procedure shifting DRG to surgical grouping
Radical cystectomy (refractory CIS)D09.0Yes — cystectomyDRG 664 (w/MCC), 665 (w/CC), 666 (w/o CC/MCC)Highest-weight DRG grouping in bladder cancer surgical pathway
D09.0 as secondary Dx, admission for hematuriaR31.0NoVaries — hematuria/urinary DRGD09.0 as secondary; CC/MCC impact varies by principal

When D09.0 is principal and TURBT is performed, the ICD-10-PCS transurethral resection/excision of bladder lesion code is the O.R. procedure that drives the surgical DRG. Radical cystectomy is the highest-acuity procedure associated with D09.0 and carries a dramatically higher DRG relative weight; coders must capture the cystectomy PCS code accurately (with or without lymph node dissection and with urinary diversion type) to ensure correct DRG grouping. BCG instillation as the sole reason for admission follows the antineoplastic immunotherapy sequencing rule (Z51.12 as principal) — a commonly missed sequencing issue in bladder cancer admissions.

đź”— Related ICD-10-CM Codes

In Situ Urinary Bladder Spectrum:

  • D09.10 — Carcinoma in situ of unspecified urinary organ (use when bladder is not specified)
  • D09.19 — Carcinoma in situ of other urinary organs (urethra, ureter, renal pelvis in situ)

Invasive Bladder Cancer Codes (D09.0 progression targets — Excludes 1):

  • C67.0 — Malignant neoplasm of trigone of bladder
  • C67.1 — Malignant neoplasm of dome of bladder
  • C67.2 — Malignant neoplasm of lateral wall of bladder
  • C67.3 — Malignant neoplasm of anterior wall of bladder
  • C67.4 — Malignant neoplasm of posterior wall of bladder
  • C67.5 — Malignant neoplasm of bladder neck
  • C67.9 — Malignant neoplasm of bladder, unspecified

Commonly Paired Additional Diagnoses:

  • R31.0 — Gross hematuria (common presenting symptom with bladder CIS)
  • R31.1 — Benign essential microscopic hematuria
  • Z85.51 — Personal history of malignant neoplasm of bladder (use when CIS is resolved; not for active D09.0)
  • Z79.899 — Long-term (current) use of other medication (e.g., BCG immunotherapy context)

🛠️ Commonly Associated CPT Codes

  • 52234 — Cystourethroscopy with transurethral resection of medium bladder tumor(s) (2.1 to 5.0 cm): TURBT is the primary diagnostic and therapeutic procedure for bladder CIS; it provides histological confirmation (in situ vs. invasive) and achieves initial tumor debulking. The CPT code selection for TURBT depends on tumor size (52224 for small ≤2 cm; 52234 for medium 2.1-5.0 cm; 52235 for large >5 cm). On the inpatient facility side, the ICD-10-PCS equivalent is the O.R. procedure driving DRG assignment. CPT 52235 covers large TURBT; these codes are mutually exclusive per NCCI edits — only one TURBT code should be reported per operative session unless multiple anatomically distinct tumors of different sizes are removed.

  • 52204 — Cystourethroscopy with biopsy: Used for diagnostic biopsy to confirm CIS pathologically. This may be performed prior to TURBT for tissue diagnosis, or as a mapping biopsy to evaluate CIS extent. When both biopsy (52204) and resection (52234/52235) are performed at the same session, NCCI edits typically bundle 52204 into the TURBT code — only the highest-value procedure should be reported unless a separately documented distinct anatomical site biopsy supports unbundling with a modifier.

  • 51720 — Bladder instillation of anticarcinogenic agent (e.g., BCG): BCG intravesical immunotherapy is the standard first-line treatment for high-risk non-muscle-invasive bladder cancer including CIS. CPT 51720 covers the instillation procedure itself. On the inpatient facility side, the corresponding ICD-10-PCS code is an introduction of therapeutic substance into the bladder. When BCG instillation is the sole reason for admission, Z51.12 (encounter for antineoplastic immunotherapy) should be sequenced as principal per ICD-10 CM Guideline I.C.2.e, with D09.0 as additional.

  • 51570 — Cystectomy, complete (simple): Radical cystectomy is performed for BCG-refractory high-risk CIS or progression to invasive disease. On the inpatient side, the PCS code for radical cystectomy (resection of bladder, open approach) drives the encounter to the highest-weighted bladder DRG grouping (DRG 664/665/666). Documentation of urinary diversion type (ileal conduit, neobladder, continent diversion) affects both the CPT code selection and the ICD-10-PCS code for the diversion procedure.

  • 52000 — Cystourethroscopy (diagnostic): Used for surveillance cystoscopy in patients with known bladder CIS on active monitoring. Surveillance cystoscopy is performed every 3 months for the first two years following CIS diagnosis and treatment. D09.0 (if CIS is still active) or Z85.51 (if resolved) supports medical necessity for these surveillance procedures.

  • 88305 — Surgical pathology, level IV (bladder biopsy/resection): Pathology examination of TURBT specimens is billed with CPT 88305. This is a professional fee code frequently billed alongside 52234/52235 on the same date of service. It is the pathology report from 88305 that establishes the in situ (D09.0) vs. invasive (C67.xx) distinction — making this an indirect but critical code in the D09.0 coding workflow.

NCCI Bundling Considerations

TURBT codes (52224, 52234, 52235) bundle with diagnostic cystoscopy (52000) and cystoscopy with biopsy (52204) per NCCI edits when performed at the same operative session. Only the highest-level resection code should be reported; biopsy codes bundle into the TURBT unless a distinct, separately documented anatomical site biopsy was performed independent of the resection site, in which case modifier 59 or XS may be applicable with supporting documentation. BCG instillation (51720) does not bundle with TURBT and may be billed on a different date of service as a separate therapeutic encounter. Pathology codes (88305) are separately billable professional fee codes and are not subject to NCCI bundling with the surgical procedure codes.

🔬 ICD-10-PCS Crosswalk

D09.0 is an ICD-10-CM diagnosis code. The following ICD-10-PCS codes are commonly assigned in inpatient encounters where D09.0 is the principal or secondary diagnosis:

  • 0TBB8ZX — Excision of Bladder, Via Natural or Artificial Opening Endoscopic, Diagnostic: This is the ICD-10-PCS code for transurethral (endoscopic) biopsy of the bladder performed for diagnostic purposes — the PCS equivalent of cystoscopy with bladder biopsy (CPT 52204). The qualifier X (diagnostic) is required to distinguish diagnostic biopsy from therapeutic excision. This is the PCS code most commonly assigned for mapping biopsies or initial biopsy procedures confirming D09.0.

  • 0TBB8ZZ — Excision of Bladder, Via Natural or Artificial Opening Endoscopic: Represents transurethral resection (TURBT) when the procedure removes a portion of the bladder (excision, not total resection). This is the most common PCS code in D09.0 inpatient encounters; the endoscopic approach (via natural or artificial opening endoscopic = value 8) reflects the transurethral route. The distinction between Excision (partial removal) and Resection (complete removal) is critical: TURBT = Excision; total cystectomy = Resection.

  • 0TTB0ZZ — Resection of Bladder, Open Approach: Represents radical (complete) cystectomy via open approach — performed for BCG-refractory CIS or progression to invasive disease. This is a high-acuity O.R. procedure associated with the highest-weighted bladder DRGs (664/665/666). Accurate documentation of open vs. robotic-assisted approach is needed for correct PCS character selection.

  • 3E0L7GC — Introduction of Other Therapeutic Substance into Genitourinary Tract, Via Natural or Artificial Opening: The ICD-10-PCS code for intravesical BCG instillation. The body system is Genitourinary Tract (L), approach is Via Natural or Artificial Opening (7), and substance character GC reflects other therapeutic substance. When BCG instillation is performed during an inpatient admission, this PCS code should be captured as an additional procedure to support clinical documentation completeness.

đź’Š Coding Scenarios and Examples

Scenario 1 — TURBT for Newly Diagnosed Bladder CIS

A 68-year-old male was admitted for gross hematuria workup. Cystoscopy revealed a flat, erythematous lesion on the posterior bladder wall suspicious for CIS. TURBT was performed; pathology returned “urothelial carcinoma in situ, no invasion identified.” The urologist documented “carcinoma in situ of the bladder, confirmed on pathology; no evidence of muscle invasion.”

Correct Coding:

  • Principal Dx: D09.0 — Carcinoma in situ of bladder
  • Additional: R31.0 — Gross hematuria (presenting symptom)
  • ICD-10-PCS: 0TBB8ZZ — Excision of Bladder, Via Natural or Artificial Opening Endoscopic (TURBT)

Sequencing: D09.0 is principal (condition confirmed as reason for admission after study); R31.0 is additional. The TURBT PCS code shifts the DRG to the surgical grouping (DRG 673/674/675).
CDI Note: Confirm the provider’s final documented diagnosis in the discharge summary explicitly states “carcinoma in situ” — do not assign D09.0 based solely on pathology report language without provider attestation of the clinical diagnosis. If the provider’s note says “bladder cancer” or “urothelial carcinoma” without specifying in situ vs. invasive, query before assigning either D09.0 or C67.xx.

Scenario 2 — BCG Instillation Admission for Bladder CIS

A 72-year-old female with known bladder CIS (diagnosed three months prior via TURBT) was admitted for induction BCG intravesical immunotherapy. No surgical procedure was performed; BCG was instilled via catheter per protocol. The provider documented “BCG immunotherapy administration for carcinoma in situ of the bladder.”

Correct Coding:

  • Principal Dx: Z51.12 — Encounter for antineoplastic immunotherapy
  • Additional: D09.0 — Carcinoma in situ of bladder

Sequencing: Per ICD-10-CM Guideline I.C.2.e, when the reason for admission is antineoplastic immunotherapy (BCG), Z51.12 is sequenced as principal and D09.0 as additional. No O.R. procedure is performed; DRG groups to the medical DRG 698/699/700 based on CC/MCC burden.
CDI Note: BCG instillation (51720 / PCS 3E0L7GC) should be captured as the therapeutic procedure. If BCG-induced cystitis develops during the admission, add the appropriate cystitis code as an additional diagnosis — it may contribute CC-level value to the encounter.

Scenario 3 — Radical Cystectomy for BCG-Refractory Bladder CIS

A 65-year-old male with high-risk bladder CIS that failed two full courses of BCG immunotherapy was admitted for robotic-assisted radical cystectomy with ileal conduit urinary diversion. The urologist’s operative note and discharge summary documented “BCG-refractory carcinoma in situ of the bladder; radical cystectomy with ileal conduit performed.”

Correct Coding:

  • Principal Dx: D09.0 — Carcinoma in situ of bladder
  • ICD-10-PCS: 0TTB4ZZ — Resection of Bladder, Percutaneous Endoscopic Approach (robotic-assisted)
  • ICD-10-PCS: (Ileal conduit construction codes — urinary diversion)
  • Additional: Z87.39 — Personal history of BCG therapy / relevant history if applicable

Sequencing: D09.0 is principal (CIS is the condition driving the surgical admission); radical cystectomy PCS code is the O.R. procedure driving DRG 664/665/666 (highest-weight bladder DRG grouping). The ileal conduit PCS codes must also be captured as additional procedures.
CDI Note: Confirm the provider explicitly documents “BCG-refractory” or “BCG failure” — this is clinically significant documentation that justifies the escalation to radical cystectomy for an in situ disease. If pathology from the cystectomy specimen shows unexpected invasive disease, a CDI query may be needed to determine whether the final discharge diagnosis should be updated to reflect invasive carcinoma (C67.xx) rather than CIS.

⚠️ Coding Pitfalls and Tips

  1. Coding D09.0 when invasive bladder cancer is documented: The inverse of the most common error — if pathology shows invasive urothelial carcinoma (any T1 or greater depth), D09.0 is incorrect and C67.xx (by bladder subsite) is required. Continuing to code D09.0 when invasion has been confirmed understates disease severity, prevents HCC capture, misrepresents the clinical stage, and may create false claims exposure. If in doubt about invasion status, query the provider — never assume in situ when the documentation mentions invasion, muscle involvement, or staging beyond Tis.

  2. Sequencing BCG admission incorrectly: When the sole reason for admission is BCG intravesical immunotherapy, Z51.12 (antineoplastic immunotherapy) must be principal per ICD-10-CM Guideline I.C.2.e — not D09.0. Sequencing D09.0 as principal in a BCG-only admission is a common and auditable sequencing error. The guideline applies equally to BCG immunotherapy as it does to chemotherapy (Z51.11): the therapy encounter code takes principal position, with the cancer diagnosis as secondary.

  3. Forgetting the HCC gap — in situ vs. invasive: D09.0 generates no HCC RAF under CMS-HCC V28. In Medicare Advantage encounters, this means a patient coded solely with D09.0 contributes no risk-adjusted revenue related to their bladder neoplasm — until the disease progresses to invasive carcinoma. Coders and CDI specialists must flag any encounter where the provider’s documentation suggests disease progression (new TURBT showing lamina propria invasion, staging upgrade, change in treatment from BCG to cystectomy) as a mandatory clarification opportunity to transition to C67.xx and capture HCC 11 or 12 RAF value.

  4. Missing the TURBT PCS code that drives the surgical DRG: When TURBT is performed during an inpatient admission, the ICD-10-PCS excision of bladder (endoscopic approach) is the O.R. procedure that shifts the DRG from the lower-weighted medical DRG 698/699/700 to the surgical DRG 673/674/675. Failing to capture the TURBT PCS code — or miscoding the approach character — is a direct reimbursement loss. Review every operative report in bladder CIS admissions for any cystoscopic procedure qualifying as an O.R. procedure.

  5. Not querying when documentation says “bladder cancer” or “urothelial carcinoma” without staging: Documentation that simply says “bladder cancer” or “urothelial carcinoma” without specifying in situ (D09.0) vs. invasive (C67.xx) is insufficient for code assignment. Both D09.0 and C67.xx represent legitimate and distinct diagnoses — the coder cannot assume one over the other. A CDI query to the treating provider for clarification (in situ or invasive? Tis, T1, T2+?) is mandatory in this scenario. This is one of the most common bladder cancer documentation gaps in inpatient records.

  6. Using D09.0 for history of bladder CIS after complete remission: Once bladder CIS has been fully treated with no current evidence of disease and no active treatment, the correct code is Z85.51 (Personal history of malignant neoplasm of bladder) — not D09.0. Continuing to code D09.0 for a resolved, historical CIS diagnosis overstates active disease, inflates the clinical complexity picture inaccurately, and is non-compliant with ICD-10-CM Guideline I.C.2.d. Confirm with the provider at each encounter whether CIS is active, in remission, or resolved before assigning D09.0.

đź“š Sources

1 Centers for Disease Control and Prevention / NCHS. *ICD-10-CM Official Guidelines for Coding and Reporting, FY2026*, Section I.C.2 — Neoplasms. U.S. Department of Health and Human Services. 2025. 2 AAPC. *ICD-10 Code D09.0 — Carcinoma in situ of bladder.* AAPC Code Reference. https://www.aapc.com/codes/icd-10-codes/D09.0 3 icdlist.com. *ICD-10-CM Diagnosis Code D09.0 — Carcinoma in situ of bladder.* 2024. https://icdlist.com/icd-10/D09.0 4 FindACode. *D09.0 Carcinoma in situ of bladder — ICD-10-CM Diagnosis Codes.* 2025. https://www.findacode.com/icd-10-cm/d09.0-carcinoma-in-situ-of-bladder.html 5 MedGenius. *D09.0: Carcinoma in situ of bladder — 2025 ICD-10-CM Codes.* 2024. https://medgenius.com/icd-10-cm/codes/D09.0 6 AAPC — My Urology Coding Alert. *ICD-10: Every Detail Counts When Reporting Bladder Neoplasms.* 2017. https://www.aapc.com/codes/coding-newsletters/my-urology-coding-alert/icd-10-every-detail-counts-when-reporting-bladder-neoplasms 7 CodingAhead. *How To Use The CPT Codes for Bladder Cancer Procedures.* 2025. https://www.codingahead.com/how-to-use-the-cpt-codes-for-bladder-cancer-procedures/ 8 CMS. *ICD-10-CM/PCS MS-DRG v40.0 Definitions Manual — MDC 11, DRG 664-666, 673-675, 698-700.* Centers for Medicare & Medicaid Services. https://www.cms.gov/icd10m/version40-fullcode-cms/fullcode_cms/P0260.html 9 S10.ai. *Bladder Cancer / Bladder Carcinoma — ICD-10 Documentation Guide.* 2025. https://s10.ai/diagnoses/letter-B/bladder_cancer 10 Registry Partners. *CTR Coding Break — Bladder Cancer and Intravesical Therapy.* December 2020. https://www.registrypartners.com/ctr-coding-break-bladder-cancer-intravesical-therapy/ 11 HealthDataMax. *V24 to V28 — CMS-HCC Version 28 Risk Adjustment Model Changes.* 2023. https://healthdatamax.com/v24-to-v28

Graph View

Recent Notes